

# Stuart McPherson

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5094945/stuart-mcpherson-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85 papers	3,934 citations	25 h-index	62 g-index
113 ext. papers	5,136 ext. citations	6.1 avg, IF	5.62 L-index

#	Paper	IF	Citations
85	Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 1148-55	13.4	626
84	Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. <i>Gut</i> , <b>2010</b> , 59, 1265-9	19.2	499
83	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nature Communications</i> , <b>2014</b> , 5, 4309	17.4	362
82	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 740-751	0.7	273
81	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , <b>2020</b> , 158, 1611-1625.e12	13.3	234
80	Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. <i>Frontline Gastroenterology</i> , <b>2014</b> , 5, 211-218	2.6	168
79	Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent <i>Clostridium difficile</i> diarrhea. <i>Diseases of the Colon and Rectum</i> , <b>2006</b> , 49, 640-5	3.1	157
78	Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 389-97	13.4	133
77	How big a problem is non-alcoholic fatty liver disease?. <i>BMJ, The</i> , <b>2011</b> , 343, d3897	5.9	129
76	Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. <i>Gut</i> , <b>2017</b> , 66, 1321-1328	19.2	128
75	Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 96-102.e3	6.9	92
74	Nutrigenetics-based intervention approach for adults with non-alcoholic fatty liver disease (NAFLD): study protocol for a randomised controlled feasibility trial. <i>BMJ Open</i> , <b>2021</b> , 11, e045922	3	78
73	Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 234-8	13.4	75
72	Non-alcoholic fatty liver disease: a practical approach to treatment. <i>Frontline Gastroenterology</i> , <b>2014</b> , 5, 277-286	2.6	75
71	Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 305-13	13.4	63
70	Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 1055-62	13.4	57
69	Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2013</b> , 25, 652-8	2.2	57

68	Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. <i>Journal of Clinical Pathology</i> , <b>2013</b> , 66, 1033-45	3.9	54
67	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. <i>JHEP Reports</i> , <b>2019</b> , 1, 188-198	10.3	46
66	Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis. <i>Journal of Hepatology</i> , <b>2008</b> , 49, 1046-54	13.4	41
65	Summary of the British Transplantation Society UK Guidelines for Hepatitis E and Solid Organ Transplantation. <i>Transplantation</i> , <b>2018</b> , 102, 15-20	1.8	41
64	A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. <i>PLoS ONE</i> , <b>2017</b> , 12, e0175717	3.7	35
63	Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 101-108	3.4	35
62	Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 981-991	6.1	33
61	The degree of hepatic steatosis associates with impaired cardiac and autonomic function. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 1203-1213	13.4	26
60	Decompensated alcohol related liver disease: acute management. <i>BMJ, The</i> , <b>2016</b> , 352, i124	5.9	25
59	Targeted case finding for hepatitis B using dry blood spot testing in the British-Chinese and South Asian populations of the North-East of England. <i>Journal of Viral Hepatitis</i> , <b>2013</b> , 20, 638-44	3.4	24
58	Cholestasis secondary to anabolic steroid use in young men. <i>BMJ, The</i> , <b>2012</b> , 344, e468	5.9	22
57	A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated Cirrhosis. <i>Journal of Clinical and Experimental Hepatology</i> , <b>2018</b> , 8, 224-234	4.1	22
56	Management of decompensated cirrhosis. <i>Clinical Medicine</i> , <b>2018</b> , 18, s60-s65	1.9	21
55	Barriers and Facilitators to Mediterranean Diet Adoption by Patients With Nonalcoholic Fatty Liver Disease in Northern Europe. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1364-1371.e3	6.9	19
54	Lifestyle Behavior Change in Patients With Nonalcoholic Fatty Liver Disease: A Qualitative Study of Clinical Practice. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 1968-1971	6.9	17
53	Response to the NCEPOD report: development of a care bundle for patients admitted with decompensated cirrhosis-the first 24 h. <i>Frontline Gastroenterology</i> , <b>2016</b> , 7, 16-23	2.6	16
52	Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. <i>Frontline Gastroenterology</i> , <b>2017</b> , 8, 252-259	2.6	15
51	Convalescent plasma therapy for persistent hepatitis E virus infection. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 434-438	13.4	14

50	Republished: Non-alcoholic fatty liver disease: a practical approach to treatment. <i>Postgraduate Medical Journal</i> , <b>2015</b> , 91, 92-101	2	14
49	No evidence of the unfolded protein response in patients with chronic hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2011</b> , 26, 319-27	4	14
48	Feasibility of a Very Low Calorie Diet to Achieve a Sustainable 10% Weight Loss in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , <b>2020</b> , 11, e00231	4.2	14
47	Implementation of a Rare bundlePimproves the management of patients admitted to hospital with decompensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 1030-1038	6.1	14
46	Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 231-235	3.4	14
45	Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study. <i>Translational Behavioral Medicine</i> , <b>2020</b> , 10, 1016-1030	3.2	14
44	Improving testing for hepatitis B before treatment with rituximab. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2016</b> , 28, 1172-8	2.2	11
43	Hepatitis B in pregnancy. <i>Frontline Gastroenterology</i> , <b>2014</b> , 5, 111-117	2.6	11
42	High rate of hepatitis C reinfection following antiviral treatment in the North East England Prisons. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 449-452	3.4	11
41	Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus. <i>Transplantation Proceedings</i> , <b>2010</b> , 42, 4573-7	1.1	8
40	Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. <i>Postgraduate Medical Journal</i> , <b>2014</b> , 90, 254-66	2	7
39	Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies. <i>Journal of Hepatology</i> , <b>2017</b> , 66, S593	13.4	7
38	Efficacy and Safety of 8Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≥ in a Single-Arm, Open-Label, Multicenter Study. <i>Advances in Therapy</i> , <b>2019</b> , 36, 3458-3470	4.1	6
37	Imaging-Based Assessment of Steatosis, Inflammation and Fibrosis in NAFLD. <i>Current Hepatology Reports</i> , <b>2017</b> , 16, 298-307	1	6
36	Effects of Exercise on Liver Fat and Metabolism in Alcohol Drinkers. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 1596-1603.e3	6.9	5
35	Lesson of the month 2: Severe reactivation of hepatitis B after immunosuppressive chemotherapy. <i>Clinical Medicine</i> , <b>2014</b> , 14, 551-5	1.9	5
34	Postoperative methicillin-resistant Staphylococcus aureus enteritis following hysterectomy: a case report and review of the literature. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2005</b> , 17, 1225-7	2.2	5
33	Distance to treatment as a factor for loss to follow up of hepatitis C patients in North East England. <i>Journal of Public Health</i> , <b>2019</b> , 41, 700-706	3.5	5

32	Improving access to treatment for patients with chronic hepatitis C through outreach. <i>Frontline Gastroenterology</i> , <b>2013</b> , 4, 125-129	2.6	4
31	An alcoholic patient who continues to drink: case outcome. <i>BMJ, The</i> , <b>2006</b> , 332, 276	5.9	4
30	Persistent Hepatitis E virus infection across England and Wales 2009-2017: Demography, virology and outcomes. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 420-430	3.4	4
29	Reply to "Liver failure in human immunodeficiency virus - Hepatitis C virus coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy". <i>Journal of Hepatology</i> , <b>2016</b> , 64, 753-4	13.4	3
28	Increased cardiovascular risk and reduced quality of life are highly prevalent among individuals with hepatitis C. <i>BMJ Open Gastroenterology</i> , <b>2020</b> , 7,	3.9	3
27	Clinical performance of Determine HBsAg 2 rapid test for Hepatitis B detection. <i>Journal of Medical Virology</i> , <b>2020</b> , 92, 3403	19.7	3
26	Embedding assessment of liver fibrosis into routine diabetic review in primary care. <i>JHEP Reports</i> , <b>2021</b> , 3, 100293	10.3	3
25	Hepatitis C in a prison in the North East of England: what is the economic impact of the universal offer of testing and emergent medications?. <i>Journal of Public Health</i> , <b>2016</b> , 38, e554-e562	3.5	2
24	P54 CHASE-B (Chinese Hepatitis Awareness, Surveillance and Education): a pilot of targeted case finding for hepatitis B virus (HBV) in the British-Chinese community. <i>Gut</i> , <b>2011</b> , 60, A25-A26	19.2	2
23	Undiagnosed chronic hepatitis B is prevalent in the british-chinese community of the north east (NE) of england. <i>Gut</i> , <b>2011</b> , 60, A241-A241	19.2	2
22	Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C. <i>Wellcome Open Research</i> , <b>2021</b> , 6, 93	4.8	2
21	Factors associated with engagement and adherence to a low-energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease. <i>BMJ Open Gastroenterology</i> , <b>2021</b> , 8,	3.9	2
20	Progress towards micro-elimination of hepatitis C in the custodial setting. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 300-301	3.4	2
19	Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease.. <i>Frontline Gastroenterology</i> , <b>2021</b> , 12, 578-585	2.6	2
18	PMO-171 A pilot of targeted case finding for hepatitis B virus (HBV) and hepatitis C (HCV) in the British South Asian community. <i>Gut</i> , <b>2012</b> , 61, A143.1-A143	19.2	1
17	Combined approach for non-invasive measurement of liver pathology by MR. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 1083-1084	13.4	1
16	Viral hepatitis in 2021: The challenges remaining and how we should tackle them.. <i>World Journal of Gastroenterology</i> , <b>2022</b> , 28, 76-95	5.6	1
15	Impact of direct-acting antiviral agents on liver function in patients with chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 168-176	3.4	1

14	Digital Intervention With Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults With Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping. <i>Journal of Medical Internet Research</i> , <b>2021</b> , 23, e20491	7.6	1
13	Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C. <i>Wellcome Open Research</i> , <b>2021</b> , 6, 93	4.8	0
12	The pathway to better primary care for chronic liver disease. <i>British Journal of General Practice</i> , <b>2021</b> , 71, 180-182	1.6	0
11	PTH-090 Natural History Of Nafld: A Study Of 108 Patients With Paired Liver Biopsies. <i>Gut</i> , <b>2014</b> , 63, A249.2-A250	19.2	
10	PWE-120 High rate of false positives for advanced fibrosis when simple non-invasive fibrosis tests are used in older patients (≥5 years) with nafld. <i>Gut</i> , <b>2015</b> , 64, A265.1-A265	19.2	
9	P81 Pre-transplant histological assessment in patients with alcoholic liver disease does not predict risk of recidivism post liver transplantation. <i>Gut</i> , <b>2011</b> , 60, A37-A38	19.2	
8	OP11 Are simple non-invasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?. <i>Gut</i> , <b>2011</b> , 60, A54-A55	19.2	
7	OC-017 A comparison of non-invasive fibrosis scoring systems in patients with non-alcoholic fatty liver disease. <i>Gut</i> , <b>2010</b> , 59, A7.2-A8	19.2	
6	Acute hepatitis C in a nursing home resident. <i>Age and Ageing</i> , <b>2005</b> , 34, 188-9	3	
5	Physical Activity, Inactivity and Sleep in Patients with Significant Non-Alcoholic Fatty Liver Disease. <i>American Journal of the Medical Sciences</i> , <b>2021</b> ,	2.2	
4	Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT. <i>Efficacy and Mechanism Evaluation</i> , <b>2021</b> , 8, 1-90	1.7	
3	PTU-093a An Audit of Primary Prophylaxis Against Variceal Bleeding Amongst Patients with Cirrhosis. <i>Gut</i> , <b>2016</b> , 65, A100.3-A101	19.2	
2	PTH-107 Chronic Hepatitis B Management The UK: A National Survey of Current Practice Following Nice Guidance. <i>Gut</i> , <b>2016</b> , 65, A271.2-A272	19.2	
1	PTH-115 Increasing Access to Hepatitis C Treatment in The North East of England. <i>Gut</i> , <b>2016</b> , 65, A275-A276	19.2	